Cinctive Capital Management’s Denali Therapeutics DNLI Stock Holding History

Cinctive Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-27,792	Closed	-$404K	–	423
2025 Q3	$404K	Buy	27,792 +3,482	+14%	+$50K	0.02%	361
2025 Q2	$340K	Buy	+24,310	New	+$342K	0.02%	335
2025 Q1	–	Sell	-130,445	Closed	-$2.66M	–	356
2024 Q4	$2.66M	Sell	130,445 -18,649	-13%	-$477K	0.14%	194
2024 Q3	$4.34M	Buy	149,094 +36,771	+33%	+$911K	0.24%	141
2024 Q2	$2.61M	Buy	+112,323	New	+$2.16M	0.12%	220

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cinctive Capital Management's DNLI Position: Q4 2025 in Review

Cinctive Capital Management sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 27,792 shares — an estimated $404K sold.

Cinctive Capital Management first reported a position in DNLI in Q2 2024 and held it in 5 quarters. The position peaked at $4.34M in Q3 2024. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Cinctive Capital Management reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Cinctive Capital Management sold 27,792 Denali Therapeutics shares in Q4 2025, an estimated $404K.
Cinctive Capital Management first reported a position in Denali Therapeutics in Q2 2024 and held it in 5 quarters.
Cinctive Capital Management's Denali Therapeutics position peaked at $4.34M in Q3 2024.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Cinctive Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.